B
BEAM
Beam Therapeutics Inc.
27.43
+1.10+4.18%After Hours: 27.59 +0.16 +0.58%19:58 04/10 EDT
OPEN/PREV CLOSE26.49/26.33
TODAY RANGE25.79-27.48
VOL2.00M
MARKET CAP2.79B
52 WEEK RANGE13.53-36.44
AVG VOL (3M)2.02M
% TURNOVER1.97%
TURNOVER--
P/E (TTM)-33.9144
% RANGE6.42%
EPS(TTM)-0.8088
P/E(FORWARD)-5.9407
P/B2.254
BVPS12.17
DIVIDEND--
P/S19.97
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.75B
SHARES OUTSTANDING101.86M
NEXT EARNINGS05/04-05/08
FREE FLOAT100.39M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·4d ago
Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication
Simply Wall St·04/04 06:24
Assessing Beam Therapeutics (BEAM) Valuation After Major BEACON Trial Milestone For Sickle Cell Therapy
Seeking Alpha·04/03 18:25
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Reuters·04/01 22:32
Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares
TipRanks·04/01 21:20
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
Reuters·04/01 21:12
Beam risto-cel BEACON trial data in NEJM support BLA filing by late 2026
Seeking Alpha·03/31 12:30
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations
Seeking Alpha·03/31 10:35
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
Simply Wall St·03/28 06:11
Beam Therapeutics (BEAM) Is Down 9.9% After Advancing BEAM-302 Into FDA Accelerated Approval Pathway
TipRanks·03/28 04:56
Beam Therapeutics (BEAM) Gets a Buy from Wedbush
Dow Jones·03/26 15:45
Beam Therapeutics Price Target Raised to $68.00/Share From $64.00 by Citigroup
Dow Jones·03/26 15:45
Beam Therapeutics Is Maintained at Buy by Citigroup